{"entity":{"id":"juventas-cell-therapy","kind":"company","name":"Juventas Cell Therapy","aka":["Hebei Senlang Biotechnology"],"tldr":"Juventas Cell Therapy in Tianjin developed inaticabtagene autoleucel, the first CAR-T approved in China for leukaemia (2023).","summary":"Juventas Cell Therapy was founded in Tianjin with the Chinese Academy of Medical Sciences Institute of Hematology. Its CD19 CAR-T inaticabtagene autoleucel (CNCT19) was approved by the NMPA in November 2023 for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia, and is also in trials for large B-cell lymphoma.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.juventascell.com"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["inaticabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"Tianjin, China","country":"CN","companyType":"cell-therapy","website":"https://www.juventascell.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/juventas-cell-therapy/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"drug":[{"id":"inaticabtagene-autoleucel","kind":"drug","name":"Inaticabtagene autoleucel","route":"/drugs/inaticabtagene-autoleucel/"}]}}